GlycoMimetics (GLYC) Set to Announce Quarterly Earnings on Thursday

GlycoMimetics (NASDAQ:GLYC) will announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. The company had revenue of $0.01 million during the quarter. On average, analysts expect GlycoMimetics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GlycoMimetics Price Performance

Shares of GLYC opened at $0.31 on Wednesday. The firm has a market capitalization of $19.68 million, a price-to-earnings ratio of -0.53 and a beta of 2.30. GlycoMimetics has a 1-year low of $0.27 and a 1-year high of $3.53. The company has a 50-day moving average of $2.42 and a 200 day moving average of $2.33.

Analyst Upgrades and Downgrades

GLYC has been the topic of several research analyst reports. Capital One Financial reissued an “overweight” rating on shares of GlycoMimetics in a research note on Thursday, February 22nd. HC Wainwright reissued a “neutral” rating on shares of GlycoMimetics in a research report on Monday. Finally, StockNews.com downgraded GlycoMimetics from a “hold” rating to a “sell” rating in a report on Thursday, March 14th.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.